Monopar Therapeutics Inc. (NASDAQ:MNPR) Receives $107.00 Consensus Target Price from Analysts

Shares of Monopar Therapeutics Inc. (NASDAQ:MNPR) have been given a consensus rating of “Buy” by the thirteen ratings firms that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, ten have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $107.00.

MNPR has been the topic of a number of research analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Monopar Therapeutics in a research note on Thursday, January 22nd. Cantor Fitzgerald restated an “overweight” rating on shares of Monopar Therapeutics in a research note on Wednesday, January 21st. Chardan Capital restated a “buy” rating and issued a $100.00 price target on shares of Monopar Therapeutics in a research note on Monday, March 30th. Morgan Stanley initiated coverage on Monopar Therapeutics in a research note on Friday, January 9th. They issued an “overweight” rating and a $115.00 price target on the stock. Finally, BTIG Research restated a “buy” rating and issued a $104.00 price target on shares of Monopar Therapeutics in a research note on Monday, February 23rd.

Institutional Investors Weigh In On Monopar Therapeutics

Large investors have recently added to or reduced their stakes in the business. AlphaQuest LLC grew its holdings in Monopar Therapeutics by 8.5% in the 3rd quarter. AlphaQuest LLC now owns 1,935 shares of the company’s stock valued at $158,000 after buying an additional 151 shares in the last quarter. Russell Investments Group Ltd. acquired a new position in Monopar Therapeutics in the 3rd quarter valued at $28,000. BNP Paribas Financial Markets grew its holdings in Monopar Therapeutics by 100.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 696 shares of the company’s stock valued at $57,000 after buying an additional 349 shares in the last quarter. Meeder Asset Management Inc. acquired a new position in Monopar Therapeutics in the 4th quarter valued at $65,000. Finally, Caitong International Asset Management Co. Ltd acquired a new position in Monopar Therapeutics in the 4th quarter valued at $86,000. Institutional investors own 1.83% of the company’s stock.

Monopar Therapeutics Trading Down 3.6%

NASDAQ MNPR opened at $52.71 on Friday. Monopar Therapeutics has a 12 month low of $28.40 and a 12 month high of $105.00. The stock has a 50 day moving average of $56.22 and a 200-day moving average of $69.15. The company has a market cap of $352.63 million, a PE ratio of -28.96 and a beta of 1.64.

Monopar Therapeutics (NASDAQ:MNPR) last posted its quarterly earnings results on Friday, March 27th. The company reported ($0.61) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.10). As a group, sell-side analysts predict that Monopar Therapeutics will post -4.31 EPS for the current fiscal year.

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.